How to Evaluate a Biotech IPO: 5 Questions Before You Buy

There have been 12 biotech IPOs. Three made money. The other nine traded below issue price within a year, and two went to zero.

Here’s what the three winners had in common, and why the other nine failed.

The Problem

A biotech IPO hits your brokerage app at $18. The company is developing a drug for a disease you’ve heard of. The headline says “$300 million IPO.” You have ten minutes to decide. Buy?

Most people do. Most people lose money.

Biotech IPOs are the most dangerous IPOs in any sector. A tech company going public typically has revenue. A biotech going public typically has a Phase 1 dataset, a burn rate, and a prayer. In 2026, the IPO window is wide open: 20 biotech IPOs have priced for roughly $6.4 billion so far. But the playbook hasn’t changed: roughly 80% of biotech IPOs historically trade below issue price within 12 months.

The Solution

Before you buy a single share, answer five questions. These questions separate the 20% of biotech IPOs worth holding from the 80% that will drift, dilute you, and destroy capital.

---

Question 1: Is there a lead program with Phase 2 data, or just Phase 1?

A Phase 1 trial tests safety in 20-100 people. It tells you the drug doesn’t immediately poison anyone. That’s it. It says nothing about whether the drug works.

A Phase 2 trial tests efficacy in 100-300 patients with the disease. It gives you a real signal: does this drug move the needle on the thing it’s supposed to treat?

The difference in outcomes is stark. Only about 33% of drugs that complete Phase 2 make it to Phase 3. A Phase 1 biotech IPO is a lottery ticket with extra steps.

Open the S-1. Go to the SEC’s EDGAR system at sec.gov, search the company name, and find the “S-1/A” filing. Scroll to the “Business” section. What phase is the lead program? If the answer is Phase 1 or preclinical, the IPO is a bet on a molecule that hasn’t proven it works yet.

Real example: Scribe Therapeutics (SCTX) went public in July 2026 at $15 with a Phase 1 gene-editing program. The stock ran 59% on the CRISPR narrative. But the clinical data that matters doesn’t exist yet. Contrast with Apnimed (APMD), which went public the same month at $16, with a completed Phase 3 package and a PDUFA date of February 28, 2027. The market knows exactly what Apnimed needs to prove. See the Apnimed IPO breakdown for the details.

Question 2: Who are the existing investors, and what’s the lockup?

Every biotech S-1 lists the major shareholders: the venture funds, crossover investors, and insiders who own the company before the IPO.

Top-tier crossover funds that specialize in biotech (OrbiMed, RA Capital, venBio, Frazier Life Sciences) do real diligence. They don’t fund lottery tickets. If they led the last private round and are buying more in the IPO, that’s a positive signal.

But the lockup is where most retail investors get crushed.

A lockup period is a restriction that prevents pre-IPO shareholders from selling their shares for a set period after the IPO, typically 180 days. When the lockup expires, insiders can sell. Studies show that the bottom quartile of biotech IPOs drops 10-15% relative to the prior month when lockups expire.

The trade you need to know: Even if you identify a great biotech IPO, you may not want to buy on day one. The lockup expiration, 90-180 days later, often creates a better entry point, whether the science is good or not. Pre-IPO shareholders will sell regardless.

Red flag: The S-1’s “Use of Proceeds” and “Principal and Selling Stockholders” sections tell you whether pre-IPO shareholders are selling into the IPO. If they are, run. If the company itself is raising all the money and existing holders are locked up for 180 days, that’s standard.

Question 3: What’s the cash runway post-IPO?

Cash runway is the number of months a biotech can operate before running out of money, calculated as: cash and equivalents divided by the quarterly burn rate. Under 12 months means dilution is guaranteed. Under 6 months means avoid.

The S-1’s Management’s Discussion and Analysis (MD&A) section gives you the burn rate. Look at “Results of Operations” for R&D expenses and general and administrative costs. Add them. Multiply by four for the annual burn.

Example calculation: The IPO raised $150 million. The S-1 shows the company spent $30 million last quarter on R&D and G&A. That’s a $120 million annual burn: 15 months of runway. Expect another offering within 12 months. That offering dilutes existing shareholders by 20-30%.

A biotech with 36+ months of cash runway can fund its lead program through a data readout and an approval decision without returning to market. That’s what you want.

Question 4: Is there a catalyst within 12 months?

A catalyst is a scheduled event that moves the stock: a Phase 2 data readout, a Phase 3 enrollment completion, a PDUFA date. Without one, the stock drifts. Biotech stocks trade on catalysts, not earnings. Without a catalyst, you’re holding dead money.

Check ClinicalTrials.gov. Search the company’s lead drug on clinicaltrials.gov. Find the trial. Look at the “Estimated Primary Completion Date.” That’s your catalyst window. If the estimated completion is more than 18 months out, the stock will trade sideways until it gets closer.

Real example: Braveheart Bio (BRVE) went public in August 2026 at $18, raising $382.5 million. Its lead drug BHB-1893, a cardiac myosin inhibitor for hypertrophic cardiomyopathy licensed from China’s Hengrui, is Phase 3-ready. The Phase 3 start is a near-term catalyst. See the Braveheart IPO analysis for the competitive dynamics.

Question 5: What’s the valuation relative to peers?

A biotech IPO that prices at $1.5 billion with Phase 1 data and no platform is absurd. A $500 million valuation for a Phase 2 rare disease company with a validated mechanism and clear regulatory path is at a discount to its public peers.

The floor for valuation is set by what comparable public companies trade at. Go to the S-1’s “Business” section, find the indication, then search ClinicalTrials.gov for other drugs targeting the same disease at the same phase. Compare market caps. If the IPO is pricing at 2x the public comp with the same-stage asset, you’re overpaying.

See the biotech valuation guide for the rNPV framework that institutional investors use: the same math that tells you a $2.2 billion IPO for a Phase 1 platform company only works if everything goes perfectly, which it never does.

---

Common Mistakes

Buying at the IPO pop. Biotech IPOs often open 20-50% above the offer price. That’s the “pop.” Retail investors buying the pop are paying a premium for access that institutions got at the offer price. The post-pop drift can be slow and punishing. If you missed the offer, wait for the first pullback; it always comes.

Ignoring the lockup calendar. A biotech IPO can be up 40% six months in, and you’ll still get crushed when the lockup expires. Mark the date. Set a calendar reminder. The insiders will.

Treating every IPO like Veradermics. Veradermics (VDRX) went public in February 2026 at $17 and ran to $111, a 549% gain. It’s the standout of the 2026 class. But for every Veradermics, there’s an Eikon Therapeutics, which went public at $18 the same month and trades at $10, down 45%. The average outcome is not the outlier.

Skipping the S-1. Every answer in this guide comes from one document. If you buy a biotech IPO without reading the S-1, you’re not investing. You’re gambling.

The Checklist

Before you buy any biotech IPO:

• Phase 2 data or better? Yes = proceed. Phase 1 only = skip.
• Top-tier crossover investors holding, not selling? Check the S-1’s major shareholders and use of proceeds sections.
• Cash runway over 24 months post-IPO? Under 12 = guaranteed dilution.
• Catalyst within 12 months? Check ClinicalTrials.gov for the primary completion date.
• Valuation reasonable vs public comps? Same phase, same indication. If the comp trades at $500M and this IPO is pricing at $1.5B, you’re paying for perfection.
• Lockup expiration noted? Set a calendar reminder for 180 days out. That’s your second entry point, not your first.

Three of those 12 biotech IPOs passed all five questions. Those are the three that returned capital. The other nine? The S-1 was skipped.